Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Other Non-Current Liabilities (2016 - 2024)

Voyager Therapeutics (VYGR) has disclosed Other Non-Current Liabilities for 10 consecutive years, with $39.4 million as the latest value for Q3 2024.

  • Quarterly Other Non-Current Liabilities rose 108.09% to $39.4 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $39.4 million through Sep 2024, up 108.09% year-over-year, with the annual reading at $18.1 million for FY2023, 15.03% down from the prior year.
  • Other Non-Current Liabilities hit $39.4 million in Q3 2024 for Voyager Therapeutics, down from $41.2 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $44.4 million in Q4 2020 to a low of $18.1 million in Q4 2023.
  • Historically, Other Non-Current Liabilities has averaged $31.9 million across 5 years, with a median of $31.1 million in 2020.
  • Biggest five-year swings in Other Non-Current Liabilities: tumbled 46.3% in 2022 and later skyrocketed 109.51% in 2024.
  • Year by year, Other Non-Current Liabilities stood at $44.4 million in 2020, then dropped by 10.81% to $39.6 million in 2021, then plummeted by 46.24% to $21.3 million in 2022, then decreased by 15.03% to $18.1 million in 2023, then skyrocketed by 117.57% to $39.4 million in 2024.
  • Business Quant data shows Other Non-Current Liabilities for VYGR at $39.4 million in Q3 2024, $41.2 million in Q2 2024, and $43.0 million in Q1 2024.